UA79285C2 - Non-nucleoside reverse transcriptase inhibitors and use thereof - Google Patents

Non-nucleoside reverse transcriptase inhibitors and use thereof Download PDF

Info

Publication number: UA79285C2
Authority: UA; Ukraine
Prior art keywords: cooh; optionally substituted; svalkyl; substituted; methyl
Prior art date: 2002-05-16

Application number

UA20041210291A

Other languages

English (en)

Ukrainian (uk)

Inventor

Bruno Simoneau

Serge Landry

Eric Malenfant

Julie Naud

Meara Jeffrey O'

Bounkham Thavonekham

Christiane Yoakim

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-16

Filing date

2003-05-14

Publication date

2007-06-11

2003-05-14 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2007-06-11 Publication of UA79285C2 publication Critical patent/UA79285C2/uk

Links

229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title description 2
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 157
125000001424 substituent group Chemical group 0.000 claims abstract description 39
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 31
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 26
229910052717 sulfur Inorganic materials 0.000 claims abstract description 15
150000003839 salts Chemical class 0.000 claims abstract description 13
125000005842 heteroatom Chemical group 0.000 claims abstract description 8
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 4
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 61
229910052736 halogen Inorganic materials 0.000 claims description 34
150000002367 halogens Chemical class 0.000 claims description 34
-1 substituted Chemical class 0.000 claims description 28
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 26
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 25
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 22
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 14
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 12
125000000753 cycloalkyl group Chemical group 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 10
208000031886 HIV Infections Diseases 0.000 claims description 9
229910052799 carbon Inorganic materials 0.000 claims description 9
208000037357 HIV infectious disease Diseases 0.000 claims description 8
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 8
229930192474 thiophene Natural products 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 7
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 5
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 5
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
150000003536 tetrazoles Chemical class 0.000 claims description 4
150000003852 triazoles Chemical class 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
125000003118 aryl group Chemical group 0.000 abstract description 14
239000003112 inhibitor Substances 0.000 abstract description 14
229910052760 oxygen Inorganic materials 0.000 abstract description 7
125000001188 haloalkyl group Chemical group 0.000 abstract description 4
125000005843 halogen group Chemical group 0.000 abstract description 4
229940002612 prodrug Drugs 0.000 abstract description 3
239000000651 prodrug Substances 0.000 abstract description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
239000000243 solution Substances 0.000 description 95
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
239000000203 mixture Substances 0.000 description 60
239000011541 reaction mixture Substances 0.000 description 49
239000007864 aqueous solution Substances 0.000 description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
239000007787 solid Substances 0.000 description 40
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 33
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
238000003818 flash chromatography Methods 0.000 description 29
239000012267 brine Substances 0.000 description 24
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
239000012044 organic layer Substances 0.000 description 22
235000019439 ethyl acetate Nutrition 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 14
238000000034 method Methods 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 10
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
241000725303 Human immunodeficiency virus Species 0.000 description 10
241000713772 Human immunodeficiency virus 1 Species 0.000 description 10
102100034343 Integrase Human genes 0.000 description 10
239000003814 drug Substances 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 9
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 9
230000035772 mutation Effects 0.000 description 9
VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 9
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
238000004007 reversed phase HPLC Methods 0.000 description 8
208000030507 AIDS Diseases 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000004048 modification Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
CVLAEJNQNKXNNN-UHFFFAOYSA-N diazepin-4-one Chemical compound O=C1C=CC=NN=C1 CVLAEJNQNKXNNN-UHFFFAOYSA-N 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
239000005711 Benzoic acid Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
235000010233 benzoic acid Nutrition 0.000 description 5
235000010290 biphenyl Nutrition 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
159000000000 sodium salts Chemical class 0.000 description 5
239000012265 solid product Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
229910052786 argon Inorganic materials 0.000 description 4
239000004305 biphenyl Substances 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
239000012634 fragment Substances 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
239000010410 layer Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 4
229950001870 spizofurone Drugs 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
UDORKTOXFJWYDF-UHFFFAOYSA-N 2-bromo-1-(4-hydroxy-3-methylphenyl)ethanone Chemical compound CC1=CC(C(=O)CBr)=CC=C1O UDORKTOXFJWYDF-UHFFFAOYSA-N 0.000 description 3
IWJGMJHAIUBWKT-UHFFFAOYSA-N 4-bromo-2-methylphenol Chemical compound CC1=CC(Br)=CC=C1O IWJGMJHAIUBWKT-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 3
101100237844 Mus musculus Mmp19 gene Proteins 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000000798 anti-retroviral effect Effects 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000006260 foam Substances 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
JXYPNRIYAMXJSE-UHFFFAOYSA-N 1,4-diazepin-6-one Chemical compound O=C1C=NC=CN=C1 JXYPNRIYAMXJSE-UHFFFAOYSA-N 0.000 description 2
HBOMLICNUCNMMY-UHFFFAOYSA-N 1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(N=[N+]=[N-])C1 HBOMLICNUCNMMY-UHFFFAOYSA-N 0.000 description 2
POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
VJCJGAZNBKGBPK-UHFFFAOYSA-N 2-methyl-4-(1,3-oxazol-4-yl)phenol Chemical compound C1=C(O)C(C)=CC(C=2N=COC=2)=C1 VJCJGAZNBKGBPK-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
BMDRBIRUNXQCSB-UHFFFAOYSA-N 4-(2-amino-1,3-thiazol-4-yl)-2-methylphenol Chemical compound C1=C(O)C(C)=CC(C=2N=C(N)SC=2)=C1 BMDRBIRUNXQCSB-UHFFFAOYSA-N 0.000 description 2
YISNRQDIZMPVJB-UHFFFAOYSA-N 4-(methoxymethoxy)-3-methylbenzaldehyde Chemical compound COCOC1=CC=C(C=O)C=C1C YISNRQDIZMPVJB-UHFFFAOYSA-N 0.000 description 2
BAKYASSDAXQKKY-UHFFFAOYSA-N 4-Hydroxy-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1O BAKYASSDAXQKKY-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
LTFHNKUKQYVHDX-UHFFFAOYSA-N 4-hydroxy-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1O LTFHNKUKQYVHDX-UHFFFAOYSA-N 0.000 description 2
YHTZDGVHBUXXDE-UHFFFAOYSA-N 5-(4-hydroxy-3-methylphenyl)furan-2-carbaldehyde Chemical compound C1=C(O)C(C)=CC(C=2OC(C=O)=CC=2)=C1 YHTZDGVHBUXXDE-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000006069 Suzuki reaction reaction Methods 0.000 description 2
102000016540 Tyrosine aminotransferases Human genes 0.000 description 2
108010042606 Tyrosine transaminase Proteins 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 2
229910052796 boron Inorganic materials 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
125000002576 diazepinyl group Chemical class N1N=C(C=CC=C1)* 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000004821 distillation Methods 0.000 description 2
238000013504 emergency use authorization Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000009088 enzymatic function Effects 0.000 description 2
MZTFQHKIUKWTHJ-UHFFFAOYSA-N ethyl 3-(4-hydroxy-3-methylphenyl)-1,2-oxazole-5-carboxylate Chemical compound O1C(C(=O)OCC)=CC(C=2C=C(C)C(O)=CC=2)=N1 MZTFQHKIUKWTHJ-UHFFFAOYSA-N 0.000 description 2
HOOXMKJYQNXIIY-UHFFFAOYSA-N ethyl 5-(4-aminophenyl)-2-methylfuran-3-carboxylate Chemical compound O1C(C)=C(C(=O)OCC)C=C1C1=CC=C(N)C=C1 HOOXMKJYQNXIIY-UHFFFAOYSA-N 0.000 description 2
XLPPLSBHUUSRQG-UHFFFAOYSA-N ethyl 5-(4-hydroxyphenyl)-2-methylfuran-3-carboxylate Chemical compound O1C(C)=C(C(=O)OCC)C=C1C1=CC=C(O)C=C1 XLPPLSBHUUSRQG-UHFFFAOYSA-N 0.000 description 2
KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
229920006158 high molecular weight polymer Chemical group 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000011630 iodine Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
QBMHMOKIFSCFCX-UHFFFAOYSA-N methyl 4-hydroxy-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(O)C(C)=C1 QBMHMOKIFSCFCX-UHFFFAOYSA-N 0.000 description 2
QTPUQIPDECAPGQ-UHFFFAOYSA-N n-[[4-(methoxymethoxy)-3-methylphenyl]methylidene]hydroxylamine Chemical compound COCOC1=CC=C(C=NO)C=C1C QTPUQIPDECAPGQ-UHFFFAOYSA-N 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000005551 perinatal transmission Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
150000002989 phenols Chemical class 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000007958 sleep Effects 0.000 description 2
235000014347 soups Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
SYSFTTYJTWPOOR-UHFFFAOYSA-N (2-diphenylphosphanyl-1-naphthalen-1-yl-3h-naphthalen-2-yl)-diphenylphosphane Chemical group C1C=C2C=CC=CC2=C(C=2C3=CC=CC=C3C=CC=2)C1(P(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)C1=CC=CC=C1 SYSFTTYJTWPOOR-UHFFFAOYSA-N 0.000 description 1
JUWYQISLQJRRNT-UHFFFAOYSA-N (5-formylfuran-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)O1 JUWYQISLQJRRNT-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
OBQPKGCVMCIETH-UHFFFAOYSA-N 1-chloro-1-(1-chloroethoxy)ethane Chemical compound CC(Cl)OC(C)Cl OBQPKGCVMCIETH-UHFFFAOYSA-N 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
GSQZOLXWFQQJHJ-UHFFFAOYSA-N 3-bromo-4-methylpyridine Chemical compound CC1=CC=NC=C1Br GSQZOLXWFQQJHJ-UHFFFAOYSA-N 0.000 description 1
MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
UDLRGQOHGYWLCS-UHFFFAOYSA-N 4-bromo-1-methoxy-2-methylbenzene Chemical compound COC1=CC=C(Br)C=C1C UDLRGQOHGYWLCS-UHFFFAOYSA-N 0.000 description 1
SMSVBXDZZQOTGB-UHFFFAOYSA-N 4-bromopyridine;hydrobromide Chemical compound Br.BrC1=CC=NC=C1 SMSVBXDZZQOTGB-UHFFFAOYSA-N 0.000 description 1
DANMQSWQAGVFKV-UHFFFAOYSA-N 4-pyridin-4-ylphenol Chemical compound C1=CC(O)=CC=C1C1=CC=NC=C1 DANMQSWQAGVFKV-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
101100287724 Caenorhabditis elegans shk-1 gene Proteins 0.000 description 1
102100027835 Cell death regulator Aven Human genes 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000632511 Daviesia arborea Species 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
101000698131 Homo sapiens Cell death regulator Aven Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010061833 Integrases Proteins 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
241000989747 Maba Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000343235 Maso Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
238000006751 Mitsunobu reaction Methods 0.000 description 1
101100498160 Mus musculus Dach1 gene Proteins 0.000 description 1
101100006982 Mus musculus Ppcdc gene Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241001582326 Renia Species 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000012317 TBTU Substances 0.000 description 1
PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
229960004748 abacavir Drugs 0.000 description 1
RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical group [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229960005319 delavirdine Drugs 0.000 description 1
AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229960003804 efavirenz Drugs 0.000 description 1
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010894 electron beam technology Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
ZOFJPHGCPKKPJE-UHFFFAOYSA-N ethyl 2-methyl-5-(4-nitrophenyl)furan-3-carboxylate Chemical compound O1C(C)=C(C(=O)OCC)C=C1C1=CC=C([N+]([O-])=O)C=C1 ZOFJPHGCPKKPJE-UHFFFAOYSA-N 0.000 description 1
XZIAFENWXIQIKR-UHFFFAOYSA-N ethyl 4-bromobenzoate Chemical compound CCOC(=O)C1=CC=C(Br)C=C1 XZIAFENWXIQIKR-UHFFFAOYSA-N 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
229960004979 fampridine Drugs 0.000 description 1
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
229960004884 fluconazole Drugs 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
150000002429 hydrazines Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000002850 integrase inhibitor Substances 0.000 description 1
229940124524 integrase inhibitor Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
QVNYNHCNNGKULA-UHFFFAOYSA-N methyl 2-amino-5-bromobenzoate Chemical compound COC(=O)C1=CC(Br)=CC=C1N QVNYNHCNNGKULA-UHFFFAOYSA-N 0.000 description 1
LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019691 monocalcium phosphate Nutrition 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
239000002547 new drug Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000032696 parturition Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000012256 powdered iron Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
235000015067 sauces Nutrition 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960004556 tenofovir Drugs 0.000 description 1
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

UA20041210291A 2002-05-16 2003-05-14 Non-nucleoside reverse transcriptase inhibitors and use thereof UA79285C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38088602P	2002-05-16	2002-05-16
PCT/CA2003/000718 WO2003097644A2 (en)	2002-05-16	2003-05-14	Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number	Publication Date
UA79285C2 true UA79285C2 (en)	2007-06-11

Family

ID=29550032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20041210291A UA79285C2 (en)	2002-05-16	2003-05-14	Non-nucleoside reverse transcriptase inhibitors and use thereof

Country Status (28)

Country	Link
US (1)	US6806265B2 (pl)
EP (1)	EP1506195B1 (pl)
JP (1)	JP4230448B2 (pl)
KR (1)	KR20050008716A (pl)
CN (1)	CN1318421C (pl)
AR (1)	AR040027A1 (pl)
AT (1)	ATE412653T1 (pl)
AU (1)	AU2003229186A1 (pl)
BR (1)	BR0310033A (pl)
CA (1)	CA2485916C (pl)
DE (1)	DE60324418D1 (pl)
EA (1)	EA009178B1 (pl)
EC (1)	ECSP045432A (pl)
ES (1)	ES2315492T3 (pl)
HR (1)	HRP20041065A2 (pl)
IL (1)	IL163753A0 (pl)
MX (1)	MXPA04010409A (pl)
MY (1)	MY134646A (pl)
NO (1)	NO20044104L (pl)
NZ (1)	NZ536736A (pl)
PE (1)	PE20040365A1 (pl)
PL (1)	PL371663A1 (pl)
RS (1)	RS98004A (pl)
TW (1)	TW200404071A (pl)
UA (1)	UA79285C2 (pl)
UY (1)	UY27809A1 (pl)
WO (1)	WO2003097644A2 (pl)
ZA (1)	ZA200406912B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
EP1610797A1 (en) *	2003-03-27	2006-01-04	Boehringer Ingelheim International GmbH	Antiviral combination of nevirapine and a further antiretroviral compound
US7348338B2 (en)	2003-07-17	2008-03-25	Plexxikon, Inc.	PPAR active compounds
JP4845730B2 (ja) *	2003-07-17	2011-12-28	プレキシコン，インコーポレーテッド	Ｐｐａｒ活性化合物
GB0324269D0 (en)	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
DE102004051277A1 (de) *	2004-10-21	2006-04-27	Merck Patent Gmbh	Heterocyclische Carbonylverbindungen
AU2005311925A1 (en) *	2004-11-30	2006-06-08	Plexxikon, Inc.	Indole derivatives for use as PPAR PPAR active compounds
US20070072904A1 (en) *	2005-09-07	2007-03-29	Jack Lin	PPAR active compounds
KR20080042170A (ko) *	2005-09-07	2008-05-14	플렉시콘, 인코퍼레이티드	Ｐｐａｒ 활성 화합물
JP2009509932A (ja) *	2005-09-07	2009-03-12	プレキシコン，インコーポレーテッド	Ｐｐａｒ活性化合物
US8492428B2 (en)	2005-09-20	2013-07-23	Mayo Foundation For Medical Education And Research	Small-molecule botulinum toxin inhibitors
PE20090159A1 (es) *	2007-03-08	2009-02-21	Plexxikon Inc	COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
CA2968464A1 (en)	2014-11-25	2016-06-02	Bayer Pharma Aktiengesellschaft	Substituted pyridobenzodiazepinone-derivatives and use thereof
KR20200030584A (ko)	2017-07-21	2020-03-20	앤타바이오 에스에이에스	화합물
TWI903299B (zh)	2018-03-08	2025-11-01	美商英塞特公司	作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (en)	2018-07-02	2020-01-09	Incyte Corporation	AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN118103038A (zh) *	2021-08-20	2024-05-28	英安塔制药有限公司	17β-羟基类固醇脱氢酶13型抑制剂及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5366972A (en)	1989-04-20	1994-11-22	Boehringer Ingelheim Pharmaceuticals, Inc.	5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5705499A (en) *	1995-10-06	1998-01-06	Boehringer Ingelheim Pharmaceuticals, Inc.	8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
TWI270547B (en)	2000-06-16	2007-01-11	Boehringer Ingelheim Ca Ltd	Non-nucleoside reverse transcriptase inhibitors
US6716836B2 (en)	2001-03-22	2004-04-06	Boehringer Ingelheim (Canada) Ltd.	Non-nucleoside reverse transcriptase inhibitors
US6673791B2 (en)	2001-07-30	2004-01-06	Boehringer Ingelheim (Canada) Ltd.	Non-nucleoside reverse transcriptase inhibitors

2003
- 2003-05-06 US US10/430,116 patent/US6806265B2/en not_active Expired - Lifetime
- 2003-05-13 MY MYPI20031796A patent/MY134646A/en unknown
- 2003-05-14 EP EP03724719A patent/EP1506195B1/en not_active Expired - Lifetime
- 2003-05-14 PL PL03371663A patent/PL371663A1/pl not_active Application Discontinuation
- 2003-05-14 EA EA200401482A patent/EA009178B1/ru not_active IP Right Cessation
- 2003-05-14 JP JP2004505376A patent/JP4230448B2/ja not_active Expired - Fee Related
- 2003-05-14 UA UA20041210291A patent/UA79285C2/uk unknown
- 2003-05-14 KR KR10-2004-7018428A patent/KR20050008716A/ko not_active Withdrawn
- 2003-05-14 RS YU98004A patent/RS98004A/sr unknown
- 2003-05-14 MX MXPA04010409A patent/MXPA04010409A/es active IP Right Grant
- 2003-05-14 AU AU2003229186A patent/AU2003229186A1/en not_active Abandoned
- 2003-05-14 HR HR20041065A patent/HRP20041065A2/hr not_active Application Discontinuation
- 2003-05-14 BR BR0310033-2A patent/BR0310033A/pt not_active IP Right Cessation
- 2003-05-14 IL IL16375303A patent/IL163753A0/xx unknown
- 2003-05-14 DE DE60324418T patent/DE60324418D1/de not_active Expired - Lifetime
- 2003-05-14 ES ES03724719T patent/ES2315492T3/es not_active Expired - Lifetime
- 2003-05-14 NZ NZ536736A patent/NZ536736A/en unknown
- 2003-05-14 CN CNB038111187A patent/CN1318421C/zh not_active Expired - Fee Related
- 2003-05-14 PE PE2003000461A patent/PE20040365A1/es not_active Application Discontinuation
- 2003-05-14 CA CA002485916A patent/CA2485916C/en not_active Expired - Fee Related
- 2003-05-14 WO PCT/CA2003/000718 patent/WO2003097644A2/en not_active Ceased
- 2003-05-14 AT AT03724719T patent/ATE412653T1/de active
- 2003-05-15 TW TW092113234A patent/TW200404071A/zh unknown
- 2003-05-15 UY UY27809A patent/UY27809A1/es not_active Application Discontinuation
- 2003-05-16 AR ARP030101708A patent/AR040027A1/es unknown
2004
- 2004-08-31 ZA ZA200406912A patent/ZA200406912B/xx unknown
- 2004-09-27 NO NO20044104A patent/NO20044104L/no unknown
- 2004-11-16 EC EC2004005432A patent/ECSP045432A/es unknown

Also Published As

Publication number	Publication date
TW200404071A (en)	2004-03-16
JP2005526851A (ja)	2005-09-08
EA200401482A1 (ru)	2005-06-30
CN1653066A (zh)	2005-08-10
US6806265B2 (en)	2004-10-19
KR20050008716A (ko)	2005-01-21
CA2485916A1 (en)	2003-11-27
DE60324418D1 (de)	2008-12-11
WO2003097644A3 (en)	2004-02-05
PE20040365A1 (es)	2004-07-22
ATE412653T1 (de)	2008-11-15
UY27809A1 (es)	2003-12-31
ZA200406912B (en)	2006-06-28
ES2315492T3 (es)	2009-04-01
CA2485916C (en)	2009-12-08
EA009178B1 (ru)	2007-12-28
HRP20041065A2 (en)	2005-04-30
US20040006071A1 (en)	2004-01-08
HK1080849A1 (en)	2006-05-04
NZ536736A (en)	2006-11-30
WO2003097644A2 (en)	2003-11-27
AU2003229186A1 (en)	2003-12-02
JP4230448B2 (ja)	2009-02-25
RS98004A (sr)	2006-12-15
AR040027A1 (es)	2005-03-09
PL371663A1 (pl)	2005-06-27
EP1506195B1 (en)	2008-10-29
MY134646A (en)	2007-12-31
IL163753A0 (en)	2005-12-18
ECSP045432A (es)	2005-01-03
CN1318421C (zh)	2007-05-30
BR0310033A (pt)	2005-02-15
MXPA04010409A (es)	2005-02-17
NO20044104L (no)	2004-12-01
EP1506195A2 (en)	2005-02-16

Publication	Publication Date	Title
UA79285C2 (en)	2007-06-11	Non-nucleoside reverse transcriptase inhibitors and use thereof
US11104689B2 (en)	2021-08-31	Influenza virus replication inhibitor and use thereof
US20250376473A1 (en)	2025-12-11	Prmts inhibitor and use thereof
US11352328B2 (en)	2022-06-07	Heterocyclic compounds for the treatment of arenavirus
KR101317119B1 (ko)	2013-10-11	염증성 및 알레르기성 장애의 치료에 유용한 신규한헤테로사이클릭 화합물
KR20240021188A (ko)	2024-02-16	체크포인트 키나제 1(chk1) 억제제 및 그의 용도
WO2006106711A1 (ja)	2006-10-12	ピリジン誘導体を含有する抗真菌剤
TW200924778A (en)	2009-06-16	Amide compound
WO2019024908A1 (zh)	2019-02-07	取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
CN103842350A (zh)	2014-06-04	作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用
JPWO2018174288A1 (ja)	2020-01-23	２（１ｈ）−キノリノン誘導体
JP2006505532A (ja)	2006-02-16	非ヌクレオシド逆転写酵素インヒビター
KR102238012B1 (ko)	2021-04-09	브로모도메인 억제제인 카르볼린 유도체
CN117756812A (zh)	2024-03-26	一类prmt5抑制剂及其用途
CN111592541B (zh)	2021-09-10	大环类激酶抑制剂及其用途
EA026137B1 (ru)	2017-03-31	Кристаллы конденсированного гетероциклического соединения
TWI846353B (zh)	2024-06-21	取代的稠環化合物及其藥物組合物、製備方法和用途
KR20250116664A (ko)	2025-08-01	Tyk2의 저해제
KR102231203B1 (ko)	2021-03-22	단백질 발현 억제제를 포함하는 우울증의 예방 또는 치료용 조성물 및 이의 용도
US20060167041A1 (en)	2006-07-27	Imidazopyridine compound
CN115916756A (zh)	2023-04-04	砜衍生物
JP2018522948A (ja)	2018-08-16	三環式化合物、及び癌治療におけるそれらの使用
MD3980413T2 (ro)	2023-12-31	Imunomodulatori heterociclici în calitate de inhibitor al punctului de control PDL1
CN120737098A (zh)	2025-10-03	硝基咪唑罗丹宁乙酸类化合物及其药物组合物和用途
HK1080849B (en)	2007-09-21	Non-nucleoside reverse transcriptase inhibitors